DECISION Horizon2020

Today is #WorldHepatitisDay! We spotlight two DECISION partners deeply committed to #liverhealth:
🔬 @easlnews.bsky.social – advancing #hepatology research
🧡 @europeliver.bsky.social – amplifying the voice of liver patients
Together, we work toward a healthier future beyond ACLF.

#Cirrhosis

🔥 We’ve hit 50% recruitment in the #COMBATtrial!
Huge thanks to all involved!💙
@rautoupe.bsky.social @hopitalbeaujon.bsky.social @hospitalclinic.bsky.social @rwth.bsky.social @uni-muenster.de @brunslab.bsky.social @medblab.bsky.social @frankuschner.bsky.social

#LiverSky #ClinicalTrial

🎥 New keynote online!
Prof. Richard Moreau, Director of #EFCLIF, explores immune dysfunction in AD & #ACLF and suggests a common mechanism behind inflammation & immune deficiency.
Watch now 👉 https://youtu.be/KWoUbTsNjQM 
#LiverSky #Hepatology

🎉 Exciting news: We’ve surpassed 500 followers on @linkedin.com!
Follow us there for updates on trials, science, and more 👉 www.linkedin.com/company/deci...

#ClinicalResearch #DECISIONproject

Consider joining this event by @a-tango.bsky.social and @crowdhelix.com!
"Industrial Perspective on Drug Development Challenges for Clinical Trials"

📅 4th June 2025
🕚 11:00 am CEST / 🕙 10:00 am BST

Register via this link: inevent.uk/en/Crowdheli...

It’s #ClinicalTrialsDay! At DECISION, we’re proud of our COMBAT & PROSPECT trials advancing care in decompensated cirrhosis.
💡COMBAT Q&A videos in multiple languages help engage patients ➡️ www.youtube.com/playlist?lis...

Thanks to all who make our trials possible! #LiverResearch

✨ #PosterTour today at #EASLCongress 2025:
All our 3 Horizon2020 #LiverResearch projects in 1 session!

Topic: #Cirrhosis & #PortalHypertension
Chair: Maria Papp

💡 Big moments:

#AMMON-OHE model for post-#TIPS #encephalopathy (Rajiv Jalan)

#Terlipressin response in AKI-HRS w/ CKD (Frank Uschner)

Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin
#POSTER SAT-145-YI by Enrico Pompili (UNIBO) proposes a personalized management approach for patients with cirrhosis and ascites, based on real-world data from long-term albumin therapy. #EASL2025

🩺 Impact of diabetes mellitus on clinical outcomes in patients with acutely decompensated cirrhosis

#E_POSTER SAT-184-YI by Mimma Bonomo (UNITO) explores how coexisting diabetes mellitus affects prognosis in patients hospitalized with acute decompensation of cirrhosis.

#EASL2025

🦠The recovery failure of fecal microbiota diversity in patients after liver transplant is associated with a complicated postoperative course

#POSTER SAT-518 by @beccsipollsi.bsky.social from @rwth.bsky.social at #EASL2025

@brunslab.bsky.social
@easlnews.bsky.social

🧪 Acute kidney disease in acutely decompensated cirrhosis: impact on clinical outcomes

#POSTER SAT-122-YI by Alberto Calleri (UNITO) examines how acute kidney disease affects outcomes in patients with acutely decompensated cirrhosis.

📅 Presented at #EASLCongress | #EASL2025
@easlnews.bsky.social

❤️ Cardiac performance is impaired in patients with proven alcohol-related hepatitis and predicts 3-month mortality in this patient population

#POSTER SAT-503-YI by Pierre-Emmanuel Rautou (@inserm.fr, APHP, EF CLIF)

📅 Presented at the #EASLCongress | #EASL2025
@easlnews.bsky.social

Back in the Abstract Session: Theresa Wirtz presents her scRNA-seq work on monocyte subsets and ACLF risk.

@rwth.bsky.social
@brunslab.bsky.social
@easlnews.bsky.social

#Cirrhosis #ACLF #EASL2025"

Estefania Huergo presents methylation data in AD patients, selected as best Young Investigator abstract in Basic Science at #EASL2025 - Congrats! 🎉
@navarrabiomed.bsky.social
@easlnews.bsky.social
#Epigenetics #LiverResearch

Javier Fernandez (FCRB) is giving the hepatologist perspective on management of MDR infections in cirrhosis as part of the EASL/ESCMID Symposium: MDR infections - a challenge in decompensated cirrhosis at #EASL2025

#LiverDisease #Cirrhosis #Hepatology @easlnews.bsky.social

Is the etiological work-up of #PSVD a one-size-fits-all?

DECISION consortium member Lucile Moga from APHP takes part in EASL/ VALDIG's session on "Do's and Don'ts in the management of Porto-Sinusoidal Vascular Disease".

#EASLCongress #EASL2025 #LiverResearch
@easlnews.bsky.social

How do you build&lead a successful research team?
The next generation of PIs learned straight from the best in today's workshop “How to Start a Research Group: From Postdoc to PI" as @rautoupe.bsky.social shared practical insights on building&maintaining a high-performing team.
@inserm.fr #EASL2025

DECISION consortium member Sophie Lotersztajn from the French research institute @inserm.fr at a late-afternoon abstract session today at #EASLCongress in Amsterdam, the Netherlands, about #fibrosis, #hepatocyte and #liver #regeneration. 🩺

#EASL2025 @easlnews.bsky.social

Congrats on presenting your poster in the Track Hub 4 this afternoon, @beccsipollsi.bsky.social ! 🙌

🔬 #POSTER FRI-222 by Thierry Gustot (EF CLIF) proposes one-week criteria to assess the appropriateness of continuing intensive care in ACLF patients who are not candidates for liver transplantation.

#EASL2025 @easlnews.bsky.social

📊 Fibroblast growth factor 19 (FGF-19) predicts transplant free-survival in critically ill patients with acute-onchronic liver failure

#POSTER FRI-199 by @beccsipollsi.bsky.social

📅 #EASLCongress | #EASL2025
@easlnews.bsky.social

🧊 Hypothermic oxygenated machine perfusion (HOPE) treatment prior to organ transplant alters key immune modulators in patients receiving liver transplantation

#POSTER FRI-495-YI by @beccsipollsi.bsky.social

📅 #EASLCongress | #EASL2025
@brunslab.bsky.social @easlnews.bsky.social

Greetings from the DECISION Investigator Meeting at #EASL2025: Study updates and collaborative discussions with Paolo Caraceni & @rautoupe.bsky.social

#ClinicalTrials #cirrhosis

Lastly at DECISION's Networking Session, Richard Moreau shares new data: high-throughput omics reveals biomarkers for infection & poor outcomes in cirrhosis.
@inserm.fr @easlnews.bsky.social sky.social

#Metabolomics #Cytokinomics #EASL2025

Next at the DECISION Networking Session at #EASL2025, Theresa Wirtz (UKA) presents scRNA-seq data showing a monocyte subset linked to ACLF risk.
Fascinating translational science in action!
@brunslab.bsky.social ky.social @easlnews.bsky.social ky.social

#scRNAseq #ACLF

Kicking off our #EASL2025 Networking Session with an intro to the DECISION project by coordinator Pierre-Emmanuel Rautou - Let’s talk systems medicine, cirrhosis, and precision care! @rautoupe.bsky.social pe.bsky.social @easlnews.bsky.social ky.social #LiverDisease

Good morning!
DECISION coordinator Pierre-Emmanuel Rautou just started the early morning abstract session on #cirrhosis at the #EASLCongress in Amsterdam. You can still join in the Benhamou Room until 09.45am! @easlnews.bsky.social

#LIVE now at #EASL2025!
⏰ 17:00 - 18:15, McIntyre Room

🧬 Learn more in this Abstract Session about "Rare Liver Diseases"!
From #Genetics to #Clinical #Innovation, rare liver diseases are taking the center stage in this focused hepatology session.
Chaired by Pavel Strnad from @rwth.bsky.social.

🧬Poster THU-159-YI
Can dimethylarginines (DAS) predict #ACLF before it strikes?
At #EASL2025, Kohilan Gananandan (@ucl.ac.uk) presents new data validating DAS as a biomarker for pre-ACLF and outcome prediction post-acute #decompensation in two large EU cohorts.
#Biomarkers #Cirrhosis #LiverResearch

"Real-world experience with long-term albumin in patients with cirrhosis and asscites" was a fascinating session. @Enrico Pompili (Bologna University) discussed long-term #albumin therapy in #cirrhosis with #ascites.
Don't miss the Poster SAT-145-YI on Saturday!
#ClinicalInsights #EASL2025